| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –
– Pro forma cash and cash equivalents from aggregate proceeds anticipated to fund operations into 2029 –
AUSTIN, TX and DURHAM, NC, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that it has entered into a securities purchase agreement for a private placement financing that is expected to result in total gross proceeds of up to approximately $103 million to Shattuck, before deducting placement agent fees and other private placement expenses.
The private placement was led by OrbiMed and with participation from both new and existing investors, including: a large healthcare-dedicated fund, Coastlands Capital, Prosight Capital, Adage Capital, Redmile Group, and NextBio Capital.
The private placement will be for an aggregate of 15,225,158 shares of the Company's common stock and, to certain investors, pre-funded warrants to purchase an aggregate of 37,410,188 shares of common stock, along with accompanying warrants to purchase an aggregate of 52,635,346 shares of common stock (or, in lieu thereof, additional pre-funded warrants). The purchase price for each share of common stock and accompanying warrant is $0.8677, with the accompanying warrant having an exercise price of $1.0846 (provided, the purchase price for each pre-funded warrant and accompanying warrant is $0.8676, with the pre-funded warrants having an exercise price of $0.0001). The pre-funded warrants are exercisable at any time after their original issuance and will not expire. The accompanying common stock warrants are immediately exercisable and expire 30 days after a public announcement of the data from the Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trials, which are expected to begin in 2026.
Posted In: STTK
